sameAs
P3781
Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast CancerEffect Of Itraconazole On The Pharmacokinetics Of PalbociclibAdjuvant Palbociclib in Elderly Patients With Breast CancerNCT Neuro Master Match - N²M² (NOA-20)An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.To Reduce the Use of Chemotherapy in Elderly Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Participants With Estrogen Receptor Positive, HER2 Negative Breast CancerStudy Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid TumorsPalbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerRadiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone MetastasisPF-06952229 Treatment in Adult Patients With Advanced Solid TumorsOlaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, Hormone Receptor-positive, HER2-negative Metastatic Breast CancerPhase II Palbociclib +Ibrutinib in Mantle Cell LymphomaPreoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for SurgeryTreatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic LeukemiaEfficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular EventFulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast CancerA Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial TumorNeoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, HER3/4 Mutation or KRAS MutationStudy of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid TumorsPD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor MalignanciesA Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 ExpressionPD0332991/Paclitaxel in Advanced Breast CancerBiological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast CancerStudy of AZD9833 Alone or in Combination With Palbociclib in Women With Advanced Breast CancerPalbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast CancerNeoadjuvant Tamoxifen, Palbociclib, Avelumab in Estrogen Receptor Positive Breast CancerAvelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaEfficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene AberrationsUlixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid TumorsDeterminants of Resistance to First-line Therapy With an AI and Palbociclib for HR+ MBCFulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to FulvestrantEndocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast CancerPalbociclib and Cetuximab in Metastatic Colorectal CancerPost Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE®PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studYLos Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell CarcinomaThe Resistance and Immune Response to Palbociclib in Breast CancerHR+/HER2- Advanced Breast Cancer and Endocrine Resistance
P4844
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma.Palbociclib: first global approval.CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity.Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors.PD0332991 (palbociclib) for treatment of pediatric intracranial growing teratoma syndrome.Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?Combined Androgen receptor blockade overcomes the resistance of breast cancer cells to palbociclibCDK4/6 inhibition alone and in combination for non-small cell lung cancerSafety and efficacy profile of cyclin-dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta-analysis of clinical trialsPreclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft modelsTherapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential targetPalbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-upTargeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic VirotherapyPalbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage responsePalbociclib Extends Survival in Advanced Breast Cancer
P921
description
chemická sloučenina
@cs
chemische Verbindung
@de
chemische verbinding
@nl
component quimic
@oc
compost químic
@ca
composto chimico
@it
composto químico
@gl
composto químico
@pt
composto químico
@pt-br
compuesto quimico
@an
name
Palbociclib
@de
Palbociclib
@gl
Palbociclib
@ro
Palbociclib
@vi
Palbociklib
@sh
Palbociklib
@sr
Palbocyklib
@pl
palbociclib
@en
palbociclib
@fr
palbociclib
@nl
type
label
Palbociclib
@de
Palbociclib
@gl
Palbociclib
@ro
Palbociclib
@vi
Palbociklib
@sh
Palbociklib
@sr
Palbocyklib
@pl
palbociclib
@en
palbociclib
@fr
palbociclib
@nl
altLabel
6-Acetyl-8-cyclopentyl-5-methy ...... H-pyrido(2,3-d)pyrimidin-7-one
@en
6-acetyl-8-cyclopentyl-5-methy ...... rido[2,3-d]pyrimidin-7(8H)-one
@en
Ibrance®
@en
PD 0332991
@en
PD 332991
@en
PD-0332991
@en
PD0332991
@en
Palbociclib
@en
UNII-G9ZF61LE7G
@en
palbociclib
@nn
prefLabel
Palbociclib
@de
Palbociclib
@gl
Palbociclib
@ro
Palbociclib
@vi
Palbociklib
@sh
Palbociklib
@sr
Palbocyklib
@pl
palbociclib
@en
palbociclib
@fr
palbociclib
@nl